Understanding Immunity to the Flu Vaccine in COVID-19 Patients
NCT ID: NCT04579588
Last Updated: 2025-11-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
230 participants
OBSERVATIONAL
2020-10-29
2026-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
COVID-19 participants
Flu shot
All participants will receive a single shot of the flu vaccine
Control participants
Flu shot
All participants will receive a single shot of the flu vaccine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Flu shot
All participants will receive a single shot of the flu vaccine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with COVID-19 at least 2 months prior enrollment
* Patients with or without obesity, diabetes, chronic fatigue and/or long term COVID-19 symptoms
* Patients without COVID-19 diagnosis for controls
Exclusion Criteria
* Pregnant or lactating
* Patients with special risks attendant to venipuncture
* Use of immunomodulatory medications that may impact vaccine immune response per clinician's judgment
* Contraindication to the flu vaccine
* Immunodeficiency or autoimmune disease that may impact vaccine immune responses per clinician's judgement
9 Years
64 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Stanford University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sayantani B. Sindher
Associate Professor of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sayantani Sindher, MD
Role: PRINCIPAL_INVESTIGATOR
Stanford University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford University
Palo Alto, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
SNP Center Inquiry
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB-58356
Identifier Type: -
Identifier Source: org_study_id